NCT02112916
Clinical Trial Information
Trial Number: NCT02112916 (ClinicalTrials.gov)
Disease Type:
- Hematopoietic Neoplasm/Leukemia - Acute Lymphoblastic Leukemia
- Hematopoietic Neoplasm/Lymphoma - Non-Hodgkin Lymphoma
Trial Title:
A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LLy)
Study ID:
AALL1231
Images are available?:
No
Is this a NCI-MATCH Trial?:
No
Datasets Linked to Trial
| Title | Description |
|---|---|
| NCT02112916-D2 | NCT02112916-D2: There are two data submissions for PMID 35271306. This dataset, NCT02112916-D2, provides specific incidence of adverse events in interest, as presented in Supplemental Table 15 “Toxicity Comparison AALL1231 vs AALL0434” . It includes patients enrolled on COG study AALL1231 and AALL0434 who experienced targeted grade 3+ adverse events. The data cutoff is 09/30/2021. |
| NCT02112916-D1 | NCT02112916-D1: There are two data submissions for PMID 35271306. This dataset, NCT02112916-D1, provides the information presented in all tables, figures, and numbers in the manuscript, except for Supplemental Table 15 . It includes all patients who enrolled on COG study AALL1231 and AALL0434. There is one row for each patient enrolled. The data cutoff is 09/30/2021. |
Accessibility | Disclaimer | FOIA | HHS Vulnerability Disclosure | Privacy & Security
U.S. Department of Health and Human Services | National Institutes of Health | National Cancer Institute | USA.gov
NIH…Turning Discovery Into Health®